An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas

Overview

Journal J Oncol

Specialty Oncology

Date 2021 Dec 28

PMID 34961815

Authors

Gang Xiao

Xuan Gao

Lifeng Li

Chao Liu

Zhiyuan Liu

Haiqin Peng

Xuefeng Xia

Xin Yi

Rongrong Zhou

Affiliations

Soon will be listed here.

Abstract

Background: mutation is the most common in diffuse LGGs, correlated with a favorable prognosis. However, the -mutant LGGs patients with poor prognoses need to be identified, and the potential mechanism leading to a worse outcome and treatment options needs to be investigated.

Methods: A six-gene immune-related prognostic signature in -mutant LGGs was constructed based on two public datasets and univariate, multivariate, and LASSO Cox regression analysis. Patients were divided into low- and high-risk groups based on the median risk score in the training and validation sets. We analyzed enriched pathways and immune cell infiltration, applying the GSEA and the immune evaluation algorithms.

Results: Stratification and multivariate Cox analysis unveiled that the six-gene signature was an independent prognostic factor. The signature (0.806/0.795/0.822) showed a remarkable prognostic performance, with 1-, 3-, and 5-year time-dependent AUC, higher than for grade (0.612/0.638/0.649) and 1p19q codeletion status (0.606/0.658/0.676). High-risk patients had higher infiltrating immune cells. However, the specific immune escape was observed in the high-risk group after immune activation, owing to increasing immunosuppressive cells, inhibitory cytokines, and immune checkpoint molecules. Moreover, a novel nomogram model was developed to evaluate the survival in -mutant LGGs patients.

Conclusion: The six-gene signature could be a promising prognostic biomarker, which is promising to promote individual therapy and improve the clinical outcomes of -mutant gliomas. The study also refined the current classification system of -mutant gliomas, classifying patients into two subtypes with distinct immunophenotypes and overall survival.

References

Persano L, Pistollato F, Rampazzo E, Della Puppa A, Abbadi S, Frasson C . BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis. 2012; 3:e412. PMC: 3481140. DOI: 10.1038/cddis.2012.153. View

Kohanbash G, Carrera D, Shrivastav S, Ahn B, Jahan N, Mazor T . Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017; 127(4):1425-1437. PMC: 5373859. DOI: 10.1172/JCI90644. View

Reardon D, Brandes A, Omuro A, Mulholland P, Lim M, Wick A . Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(7):1003-1010. PMC: 7243167. DOI: 10.1001/jamaoncol.2020.1024. View

OFarrell A, Liu Y, Moore K, Mui A . IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J. 1998; 17(4):1006-18. PMC: 1170450. DOI: 10.1093/emboj/17.4.1006. View

Xu S, Tang L, Li X, Fan F, Liu Z . Immunotherapy for glioma: Current management and future application. Cancer Lett. 2020; 476:1-12. DOI: 10.1016/j.canlet.2020.02.002. View

Chen H, Cong X, Wu C, Wu X, Wang J, Mao K . Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9 T cells. Sci Adv. 2020; 6(5):eaax4690. PMC: 6989134. DOI: 10.1126/sciadv.aax4690. View

Takei Y, Inoue K, Ogoshi M, Kawahara T, Bannai H, Miyano S . Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. FEBS Lett. 2004; 556(1-3):53-8. DOI: 10.1016/s0014-5793(03)01368-1. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Graf D, Nethisinghe S, Palmer D, Fisher A, Merkenschlager M . The developmentally regulated expression of Twisted gastrulation reveals a role for bone morphogenetic proteins in the control of T cell development. J Exp Med. 2002; 196(2):163-71. PMC: 2193926. DOI: 10.1084/jem.20020276. View

10.

Hu J, Yu A, Othmane B, Qiu D, Li H, Li C . Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 2021; 11(7):3089-3108. PMC: 7847675. DOI: 10.7150/thno.53649. View

11.

Philip B, Yu D, Silvis M, Shin C, Robinson J, Robinson G . Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Rep. 2018; 23(5):1553-1564. PMC: 6032974. DOI: 10.1016/j.celrep.2018.03.133. View

12.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

13.

Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F . Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathol Commun. 2018; 6(1):89. PMC: 6127907. DOI: 10.1186/s40478-018-0594-1. View

14.

Ou A, Ott M, Fang D, Heimberger A . The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma. Cancers (Basel). 2021; 13(3). PMC: 7865703. DOI: 10.3390/cancers13030437. View

15.

Ellrott K, Bailey M, Saksena G, Covington K, Kandoth C, Stewart C . Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018; 6(3):271-281.e7. PMC: 6075717. DOI: 10.1016/j.cels.2018.03.002. View

16.

Amankulor N, Kim Y, Arora S, Kargl J, Szulzewsky F, Hanke M . Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017; 31(8):774-786. PMC: 5435890. DOI: 10.1101/gad.294991.116. View

17.

van Dierendonck X, de Goede K, Van den Bossche J . IDH-Mutant Brain Tumors Hit the Achilles' Heel of Macrophages with R-2-Hydroxyglutarate. Trends Cancer. 2021; 7(8):666-667. DOI: 10.1016/j.trecan.2021.06.003. View

18.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

19.

Wu A, Wei J, Kong L, Wang Y, Priebe W, Qiao W . Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010; 12(11):1113-25. PMC: 3098021. DOI: 10.1093/neuonc/noq082. View

20.

Friedrich M, Sankowski R, Bunse L, Kilian M, Green E, Ramallo Guevara C . Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nat Cancer. 2022; 2(7):723-740. DOI: 10.1038/s43018-021-00201-z. View